JANUX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Campbell, Ph.D.”): 44,740,538 for, 9,631,829 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 14,627,558 for, 1,840,349 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Barrett, Ph.D.”): 44,005,362 for, 10,367,005 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 14,255,451 for, 2,212,456 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Winston Kung”): 42,187,543 for, 12,184,824 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 13,961,474 for, 2,506,433 withheld.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.

JANUX THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 53,205,989 for, 1,150,947 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 16,008,184 for, 457,264 against, 2,459 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 181 managers: 45,065,206 for, 856,880 against, 4,905 not voted, 11,262 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 70 managers: 16,621 for, 2,459 abstained, 16,448,827 1 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 174 managers: 366,585 for, 172 against, 38,100 abstained, 4,905 not voted, 42,217,226 1 year, 268,826 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

JANUX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 56,152,990 for, 27,381 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 70 asset managers below reported 16,465,169 for, 279 against, 2,459 abstained.

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.